Abstract
Introduction: AD is a chronic, systemic inflammatory disease, associated with decreased HRQoL and work productivity. Dupilumab is approved in the US for patients aged ≥6 years with moderate-to-severe AD inadequately controlled by topical therapies. We evaluated the long-term impact of dupilumab on HRQoL and work productivity outcomes among US adult AD patients from the RELIEVE-AD study, a prospective, longitudinal patient survey.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
